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Methylenetetrahydrofolate reductase (MTHFR) mutations are commonly associated with hyperhomocysteinemia,
and, through their defects in homocysteine metabolism, they have been implicated as risk factors for neural tube
defects and unexplained, recurrent embryo losses in early pregnancy. Folate sufficiency is thought to play an integral
role in the phenotypic expression of MTHFR mutations. Samples of neonatal cord blood ( ) and fetal tissuenp 119
( ) were analyzed for MTHFR C677T and A1298C mutations to determine whether certain MTHFRnp 161
genotype combinations were associated with decreased in utero viability. Mutation analysis revealed that all possible
MTHFR genotype combinations were represented in the fetal group, demonstrating that 677T and 1298C alleles
could occur in both cis and trans configurations. Combined 677CT/1298CC and 677TT/1298CC genotypes, which
contain three and four mutant alleles, respectively, were not observed in the neonatal group ( ). ThisPp .0402
suggests decreased viability among fetuses carrying these mutations and a possible selection disadvantage among
fetuses with increased numbers of mutant MTHFR alleles. This is the first report that describes the existence of
human MTHFR 677CT/1298CC and 677TT/1298CC genotypes and demonstrates their potential role in com-
promised fetal viability.
Methylenetetrahydrofolate reductase (MTHFR; E.C.
1.5.1.20 [MIM 236250]) is essential to homocysteine
metabolism (Frosst et al. 1995). Mutations in MTHFR
and other genes associated with homocysteine metabo-
lism have been reported as causes of hyperhomocysteine-
mia (Frosst et al. 1995; Jacques et al. 1996). MTHFR
mutations, however, are by far the most common eti-
ology of the mild-to-moderate form of hyperhomocys-
teinemia that is secondary to inherited enzymatic defects,
whereas folate deficiency remains the primary cause of
hyperhomocysteinemia (Isotalo and Donnelly 2000).
The best-characterized MTHFR genetic polymor-
phism is a common missense mutation consisting of a
677CrT transition (Frosst et al. 1995). This mutation
produces an alanine to valine amino acid substitution
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within the predicted catalytic domain of the MTHFR
enzyme (Frosst et al. 1995; van der Put et al. 1998). The
result is a thermolabile enzyme variant that has reduced
catalytic activity. Folate acts to stabilize this thermolabile
enzyme (Frosst et al. 1995; Rozen 1997). Homozygosity
for the thermolabile MTHFR variant predisposes indi-
viduals to the development of hyperhomocysteinemia,
especially during times of folate insufficiency (Frosst et
al. 1995; van der Put et al. 1998). Serum folate values
115.4 nM appear to neutralize the effects of 677CrT
mutations (Jacques et al. 1996).
Another common genetic polymorphism of MTHFR
is a missense mutation, consisting of a nucleotide
1298ArC transition, that results in a glutamate to al-
anine substitution (van der Put et al. 1998). Unlike the
677T mutation, the 1298C mutation is located in the
presumed regulatory domain of MTHFR (van der Put
et al. 1998;Weisberg et al. 1998). In addition, the 1298C
mutation, in either the heterozygous or the homozygous
state, does not appear to cause elevations in plasma
homocysteine. However, combined heterozygosity for
both 677T and 1298C mutations, which produces a
677CT/1298AC genotype, does result in significant
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Table 1
Individual MTHFR Genotype Distributions for Neonatal and Fetal
Groups
MTHFR
GENOTYPE
OBSERVED FREQUENCY
Pa
Neonatal Group
( )np 119
Fetal Group
( )np 161
677CC .571 .596 .714
677CT .311 .373 .311
677TT .118 .031 .007
1298AA .361 .342 .800
1298AC .563 .515 .468
1298CC .076 .143 .090
a By Fisher’s exact test.
plasma homocysteine elevations (van der Put et al.
1998).
Neural tube defects (NTDs), stillbirths, and recurrent
abortions have all been associated with hyperhomocys-
teinemia (Wouters et al. 1993; Mills et al. 1995).
Through their defects in homocysteine metabolism,
MTHFR mutations have also been implicated as risk
factors for NTDs (van der Put et al 1995, 1998; White-
head et al. 1995; Christensen et al. 1999; Shields et al.
1999) and unexplained, recurrent embryo losses in early
pregnancy (Nelen et al. 1997). Because most NTD-risk
studies that have investigated the role of MTHFR mu-
tations have focused on living children and parents, in-
trauterine fetal demise secondary to MTHFR mutations
cannot be dismissed (Christensen et al. 1999). We have
previously shown that these mutations can occur in cis
configurations; however, we have not observed 677T
alleles in the presence of homozygosity for the 1298C
allele (Isotalo and Donnelly 2000). To investigate the
relationship between MTHFR mutations and fetal via-
bility, we examined the prevalence of both neonatal and
fetal MTHFR C677T and A1298C mutations, to deter-
mine whether certain MTHFR genotype combinations
were underrepresented in either group.
All procedures were performed in accordance with the
guidelines of the institutional review board of the Ot-
tawa Hospital and with appropriate informed consent.
The study group consisted of 161 fetal tissue samples
from both spontaneous and therapeutic terminations of
pregnancy. This study group was consecutively selected;
however, the method of case recruitment precluded the
inclusion of embryos lost during very early pregnancy.
Sex distribution and the presence or absence of NTDs
could not be determined in this group. For the control
group, 119 neonates were randomly selected, and um-
bilical cord–blood samples were obtained from each. No
exclusion criteria existed for the control group, which
was composed of samples from 57 female and 62 male
infants. No cases of NTDs or homocysteinuria occurred
in the control group.
Genomic DNA was extracted from formalin-fixed fe-
tal tissue and neonatal cord whole blood, by use of the
Promega Wizard genomic–DNA extraction kit (Pro-
mega) according to the manufacturer’s protocol. To de-
tect MTHFR 677CrT and 1298ArC mutations, PCR
amplification and RFLP analysis were performed ac-
cording to published techniques (Donnelly and Rock
1999; Isotalo and Donnelly 2000). The 677CrT mu-
tation introduces a new HinfI restriction site that results
in digestion of a 198-bp PCR amplicon into 175- and
23-bp fragments. The 1298ArC mutation abolishes an
MboII restriction site resulting in a 163-bp amplicon that
is digested into four fragments of 84, 31, 30, and 18 bp.
The wild-type 1298AA genotype yields an amplicon di-
gest of five fragments of 56, 31, 30, 28, and 18 bp.
Digested PCR fragments were separated electrophoret-
ically, by use of 1% agarose (Gibco-BRL) and 2.5%
MetaphorTM agarose gels (FMC Bioproducts) prepared
with 1 # Tris-borate EDTA (Sigma) and ethidium bro-
mide (Sigma).
MTHFR allele frequencies and the prevalences of sin-
gle and combined MTHFR genotypes were determined
for the study group and the control group and were
compared by a two-tailed Fisher’s exact test. Statistical
significance was defined as . Statistical analysisP ! .05
was performed using GraphPad InStatTM (GraphPad
Software).
Individual MTHFR genotype distributions for neo-
natal and fetal groups are presented in table 1. The
677TT genotype was more prevalent in the neonatal
group at 11.8% than in the fetal group (3.1%) (Pp
). No individual MTHFR genotypes, other than.0068
the 677TT genotype, showed statistically significant dif-
ferences in distribution between groups. Combined
MTHFR C677T/A1298C genotype distributions for
both groups are presented in table 2, along with the
frequencies of single MTHFR alleles. MTHFR muta-
tions were common. The 677T allele frequency was .217
and .273 for the fetal and neonatal groups, respectively,
whereas the 1298C allele frequency was .401 and .357,
respectively, for the same groups. Analysis of combined
MTHFR genotypes revealed an increased prevalence of
677TT/1298AA genotypes in the neonatal group com-
pared with the fetal group ( ). In addition, com-Pp .001
bined 677CT/1298CC and 677TT/1298CC genotypes,
which correspond to triple- and quadruple-mutation
combinations, respectively, were not observed in the neo-
natal group but were observed at low frequencies in the
fetal group ( ). All possible combinedMTHFRPp .0402
genotypes were represented in the fetal group. Within
the neonatal group, there was no significant sex-distri-
bution difference (data not shown) between the single
and the combined MTHFR genotypes.
Combined MTHFR 677TT/1298AC genotypes were
identified at low frequencies in both the fetal and the
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Table 2
Combined C677T/A1298C MTHFR Genotype Frequencies and Allele Frequencies for Neonatal and Fetal
Groups
GENOTYPE OR ALLELE
OBSERVED FREQUENCY
ODDS RATIO (95% CI) Pb
Neonatal Group
( )anp 119
Fetal Group
( )np 161
MTHFR C677T/A1298C genotype:
CC/AA .143 .155 1.1 (.57–2.2) .866
CC/AC .353 .335 .93 (.6–1.5) .800
CC/CC .076 .107 1.3 (.6–3.2) .415
CT/AA .117 .174 .2 (.8–3.2) .237
CT/AC .193 .168 .8 (.5–1.6) .637
CT/CC NO .031 8.4 (.5–153.5) .074
TT/AA .101 .012 .1 (.02–.5) .001
TT/AC .017 .012 .7 (.1–5.3) 1.000
TT/CC NO .006 2.2 (.1–55.4) 1.000
Combined CT/CC and TT/CC NO .037 10.0 (.6–179.2) .040
MTHFR allele:
677C .727 .783
677T .273 .217
1298A .643 .599
1298C .357 .401
a NO p not observed.
b By Fisher’s exact test.
neonatal groups and demonstrated that MTHFR mu-
tations could occur in cis configurations. This provides
evidence that crossover of MTHFR 677CrT and
1298ArC mutations has occurred in the study popu-
lation.
The regulation of homocysteine metabolism is com-
plex and is dependent on multiple vitamin cofactors,
including folate, pyridoxine and vitamin B12 (Jacques et
al. 1996). Both vitamin-cofactor deficiencies and enzyme
deficiencies may contribute to hyperhomocysteinemia.
Folate deficiency is the leading cause of hyperhomocys-
teinemia; however, MTHFR mutations also affect folate
metabolism, resulting in increased homocysteine.
Both hyperhomocysteinemia and MTHFR mutations
have been associated with NTDs (van der Put et al. 1995,
1998; Whitehead et al. 1995; Christensen et al. 1999;
Shields et al. 1999). Folate sufficiency is believed to play
a critical role in the phenotypic expression of these mu-
tations. Outright folate deficiency is uncommon in
women who give birth to neonates with NTDs; there-
fore, periconceptional folate therapy does more than
correct a nutritional deficiency (Shields et al. 1999). One
of its effects is probably to stabilize MTHFR mutations
and, thereby, to reduce the severe phenotypic expression
of these mutations. In addition to NTDs, decreased fetal
viability secondary to MTHFR mutations has been re-
ported by Nelen et al. (1997), who demonstrated that
maternal homozygosity for the 677T mutation was as-
sociated with a twofold- to threefold-increased risk for
recurrent loss of an embryo during early pregnancy. In
their examination of 18 fetuses with anencephaly, en-
cephalocele, and/or spina bifida, Stegmann et al. (1999)
found no significant deviation in MTHFR genotype dis-
tribution in affected fetuses and controls. They con-
cluded that extreme forms of NTDs, those more likely
to be associated with compromised fetal viability, are
unlikely to be the result of MTHFR polymorphisms. We
provide evidence to suggest that combined MTHFR
677T and 1298Cmutations may be responsible for com-
promised fetal viability.
Examination of combined genotypes revealed that all
possible MTHFR-allele combinations were represent-
ed in the fetal group. In the neonatal group, both the
MTHFR 677CT/1298CC and the 677TT/1298CC ge-
notypes were absent. Combined, these genotypes exhib-
ited a statistically significant distribution difference,
compared with what is seen in the fetal group (Pp
). We have also observed the absence of 677CT/.0402
1298CC and 677TT/1298CC genotypes in an adult pop-
ulation consisting of healthy controls and patients with
venous thrombosis ( ) (Isotalo and Donnellynp 129
2000). The 677CT/1298CC and 677TT/1298CC com-
bined genotypes are significant, because they carry three
and four mutant MTHFR alleles, respectively. The ab-
sence of quadruple and certain triple MTHFR-mutation
combinations, in both neonates and adults (Isotalo and
Donnelly 2000), may be secondary to compromised fetal
viability, because 677T and 1298Cmutations are known
to interact in vivo (van der Put et al. 1998; Weisberg et
al. 1998). It is interesting to note that MTHFR 677TT/
1298AC genotypes, which also contain three mutant al-
leles, were represented in both groups, indicating a po-
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tential in vivo enzymatic-activity difference between the
677CT/1298CC genotype and the 677TT/1298AC
genotype. It is unknown how the polymorphisms at po-
sitions 677 and 1298 interact with each other. MTHFR
is a dimeric protein that increases the number of phe-
notypic forms that can be predicted for certain geno-
types. Although there is no evidence that the dimeric
form of this protein shows cooperativity between the
two subunits, it is likely that certain phenotypes, par-
ticularly those which arise from compound heterozy-
gotes, have either decreased stability or altered catalytic
activity as is the case when only the 677T allele is
considered.
The 677TT genotype was observed less frequently in
fetuses than in neonates ( ) and was also ac-Pp .0068
companied by a nearly 10-fold increase in frequency of
677TT/1298AA combined genotypes in the neonatal
group, compared with the fetal group ( ). ThePp .001
MTHFR 677TT/1298CC genotype was also uncommon
in the fetal group, although the 677CT/1298CC geno-
type was more prevalent. Because both these genotypes
appear to carry a selection disadvantage and to lead to
compromised fetal viability, there would be proportion-
ally greater removal of 677CT genotypes than of 677TT
genotypes. This selection effect could explain the in-
creased 677TT and 677TT/1298AA genotype represen-
tation in our neonatal group.
Complete linkage disequilibrium between the
MTHFR 677T and 1298C mutations has been sug-
gested, because the majority of studies examining these
mutations have identified them in trans positions only
(van der Put et al. 1998; Rady et al. 1999; Stegmann et
al. 1999). Weisberg et al. (1998) have identified one child
with an NTD who had an MTHFR 677TT/1298AC
genotype, providing evidence that cis configurations of
MTHFR mutations do occur. In a previous study of
MTHFR mutation prevalence in patients with venous
thrombosis and in a control group, we identified a
677TT/1298AC genotype frequency of 9.2% and
12.5%, respectively, for these groups. This finding
clearly indicates that, if linkage disequilibrium between
MTHFR mutations is present, it is incomplete (Isotalo
and Donnelly 2000). In spite of the short physical dis-
tance (2.1 kb) between MTHFR mutation loci, we have
observed evidence of recombinant events between
MTHFR mutations in both the fetal and the neonatal
groups. The identification of cis MTHFR mutations is
significant, because it allows more than two mutant al-
leles to be present in the genome of a fetus. van der Put
et al. (1998) theorized that, if cis configurations of
MTHFR mutations occurred, they would result in a se-
lection disadvantage because of the expression of severe
phenotypes, a category that could include both NTDs
and spontaneous abortions. The identification of
677CT/1298CC and 677TT/1298CC genotypes in the
fetal group provides further evidence for the cis config-
uration of MTHFR mutations. The absence of these
same genotype combinations in the neonatal group sug-
gests that additional MTHFR mutations in cis are po-
tentially deleterious or lethal. This is the first report that
describes the existence of human MTHFR 677CT/
1298CC and 677TT/1298CC genotypes and that dem-
onstrates their potential role in compromised fetal
viability.
The inherent limitation of our study (and others that
have examined the role of MTHFR mutations in con-
tributing to NTDs and/or decreased fetal viability) is that
there is bias toward late-pregnancy outcomes. Because
the majority of spontaneous abortions occur before
pregnancy is even identified clinically, the true contri-
bution of MTHFR mutations to fetal viability may be
difficult to determine. Larger prospective studies of both
viable and nonviable fetuses, along with multigenera-
tional genotyping, may further elucidate the relationship
between MTHFR genotypes and clinical outcomes.
In summary, combined MTHFR mutations likely
carry a selective disadvantage and contribute to de-
creased fetal viability, especially during times of folate
insufficiency. MTHFR 677T and 1298C mutations, de-
spite the short physical distance between their loci, have
shown evidence of allele crossover in our study popu-
lation. This study provides evidence that the combined
effects of multiple mutations on phenotype, particularly
in the case of common polymorphisms, are not restricted
to intergenic interactions. The recognition that com-
bined MTHFR genotypes may influence pregnancy out-
comes further demonstrates both the clinical significance
of this gene and the potential protective role of folate
sufficiency.
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